Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Miami, Florida 33181


Purpose:

To evaluate the potential pharmacokinetic interaction between nevirapine and clarithromycin, and to determine the effects of nevirapine on cytochrome P450 3A4 (CYP3A4) activity in vivo.


Study summary:

The study is conducted in two separate groups. Patients in Group I receive clarithromycin orally for 32 days and nevirapine orally for 28 days. Patients in Group II receive erythromycin intravenously on days 0, 14, 28, and 43 and nevirapine orally for 28 days.


Criteria:

Inclusion Criteria Concurrent Medication: Allowed: Antiretroviral drugs (i.e., zidovudine, zalcitabine, stavudine, lamivudine, didanosine, indinavir, saquinavir) provided that there has been no change in dosing of the medication > 25% within 4 weeks of study entry. Patients must have: - HIV positive status. - CD4 count >= 100 cells/mm3. Prior Medication: Allowed: Patients may be on clarithromycin at study entry. Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded: Malabsorption, severe chronic diarrhea, or inability to maintain adequate oral intake. Concurrent Medication: Excluded: Macrolide antibiotics (erythromycin, azithromycin, dirithromycin), azole fungals (ketoconazole, fluconazole, itraconazole), rifampin, rifabutin, phenytoin, terfenadine, astemizole, cisapride, triazolam, midazolam, other non-nucleoside reverse transcriptase inhibitors, antibiotics containing clavulanic acid, and Augmentin. Patients with the following prior conditions are excluded: - History of drug allergy or known drug hypersensitivity. - History of clinically important disease including hepatic, renal, cardiovascular, or gastrointestinal disease. Prior Medication: Excluded: - Investigational drugs or antineoplastic agents within 12 weeks of study entry. - Participation in a clinical trial that used ERMBY within one year of study entry. - Systemic treatment with drugs known to be potent hepatic enzyme inducers or inhibitors (e.g., oral macrolide antibiotics, azole antifungals, cimetidine, rifampin, rifabutin, and carbamazepine) within 28 days of study entry. - Use of protease inhibitors; ritonavir, nelfinavir, indinavir, or non-nucleoside reverse transcriptase inhibitor compounds e.g., delavirdine) within 4 weeks of study entry. Prior Treatment: Excluded: Radiotherapy within 12 weeks of study entry. Risk Behavior: Excluded: Current history (within the last year) of IVDA, ETOH, or substance abuse.


NCT ID:

NCT00002194


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Miami, Florida 33181
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.